JP2011084505A - Pancreatic function enhancing or activating inorganic compound particle - Google Patents
Pancreatic function enhancing or activating inorganic compound particle Download PDFInfo
- Publication number
- JP2011084505A JP2011084505A JP2009237888A JP2009237888A JP2011084505A JP 2011084505 A JP2011084505 A JP 2011084505A JP 2009237888 A JP2009237888 A JP 2009237888A JP 2009237888 A JP2009237888 A JP 2009237888A JP 2011084505 A JP2011084505 A JP 2011084505A
- Authority
- JP
- Japan
- Prior art keywords
- inorganic compound
- compound particles
- pancreatic function
- weight
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明は膵臓機能強化用無機化合物粒子に関するものであり、より詳しくは、マグネシウム（Ｍｇ）またはカルシウム（Ｃａ）の水酸化物、酸化物、炭酸化物の少なくとも１種の無機化合物に微量のバナジウム（Ｖ）化合物を添加して、バナジウム固溶無機化合物粒子とすることにより、膵臓機能強化および活性化、すなわち、血糖値を下げ、糖尿病、膵炎等の膵臓病の予防ないし治療に優れた効果を有し、さらに体内吸収力が優れたバナジウムおよびマグネシウムまたはカルシウム補給剤としての効果を併せ持つ無機化合物粒子に関する。 The present invention relates to inorganic compound particles for enhancing pancreatic function, and more specifically, a trace amount of vanadium (at least one inorganic compound of magnesium (Mg) or calcium (Ca) hydroxide, oxide and carbonate). V) Addition of compounds to form vanadium solid-solubilized inorganic compound particles enhances and activates pancreatic function, that is, lowers blood glucose levels and has an excellent effect in preventing or treating pancreatic diseases such as diabetes and pancreatitis. Furthermore, the present invention relates to an inorganic compound particle having an effect as a vanadium and magnesium or calcium supplement with excellent absorption capacity in the body.
膵臓は、消化酵素を含む膵液を分泌し、それを消化管へ送り込む。膵液中にはたんぱく質分解酵素であるキモトリプシンやトリプシン、炭水化物の分解に働くアミラーゼ、脂質の分解に働くリパーゼなどが含まれており、食物の分解に寄与する。また膵臓の中のランゲルハウス島はインシュリン、グルカゴンなどのホルモンを血液中に分泌する。
膵臓が原因の病気としては、膵炎、糖尿病があるが、糖尿病は患者が年々増えているにもかかわらず、完治が難しい病気であるとされている。糖尿病は膵臓からのインシュリンの分泌低下や、分泌作用が十分でなくなるために起こり、重症になると網膜症や壊疽、心筋梗塞などの合併症を引きおこす。糖尿病の治療としては、インシュリンの投与がなされているが、予防・治療薬のほとんどは有機物ベースの治療薬（特許文献1）（特許文献2）である。近年、糖尿病にバナジウムが有効と言われ、Ｖ-有機錯体も提案されている（特許文献3）。
The pancreas secretes pancreatic juice containing digestive enzymes and sends it to the digestive tract. The pancreatic juice contains protein-degrading enzymes chymotrypsin and trypsin, amylase that works to break down carbohydrates, lipase that works to break down lipids, etc., and contributes to the breakdown of food. Langerhaus Island in the pancreas secretes hormones such as insulin and glucagon into the blood.
As diseases caused by the pancreas, there are pancreatitis and diabetes, but it is said that diabetes is a disease that is difficult to cure even though the number of patients is increasing year by year. Diabetes mellitus occurs because insulin secretion from the pancreas is decreased or the secretory action is insufficient, and when it becomes severe, it causes complications such as retinopathy, gangrene, and myocardial infarction. Insulin is administered as a treatment for diabetes, but most of the preventive / therapeutic drugs are organic-based therapeutic drugs (Patent Document 1) (Patent Document 2). In recent years, vanadium is said to be effective for diabetes, and V-organic complexes have also been proposed (Patent Document 3).
本発明の目的は、糖尿病、膵炎糖の膵臓病の治療乃至予防、さらに膵臓機能強化乃至活性化剤、として有用な無機化合物粒子を提供することである。すなわち、微量のＶをＭｇまたは／及びＣａの水酸化物、酸化物、炭酸化物に固溶させた無機化合物粒子を提供することである。
An object of the present invention is to provide inorganic compound particles useful as a treatment or prevention of diabetes, pancreatitis sugar pancreatic disease, and further as a pancreatic function enhancement or activator. That is, it is to provide inorganic compound particles in which a small amount of V is solid-dissolved in a hydroxide, oxide, or carbonate of Mg or / and Ca.
本発明者等は、無機系制酸剤の粘膜保護効果および潰瘍治療効果につき鋭意研究の結果、これら人体に不足しがちな微量のＶをＭｇ化合物または／及びＣａ化合物に固溶させた無機化合物粒子が、血糖値を下げ、さらに膵臓機能の強化乃至活性化、すなわち、糖尿病、膵炎等の予防乃至治療に優れた効果があることをも見出した。 As a result of earnest studies on the mucosal protective effect and ulcer treatment effect of inorganic antacids, the present inventors have made an inorganic compound in which a trace amount of V which tends to be deficient in the human body is dissolved in Mg compound and / or Ca compound. It has also been found that the particles have an excellent effect in lowering blood glucose levels and further enhancing or activating pancreatic function, that is, preventing or treating diabetes, pancreatitis and the like.
本発明者は、人間が必要とするミネラルの一つであるバナジウムイオンの微量を、Ｍｇまたは／及びＣａ化合物に固溶させた下記式（1）、（2）及び（3）で表される無機化合物を経口投与することにより、血糖値を下げることができることを見出した。
Ｍ1-x(Ｖ)x(OH)2 （1）
Ｍ1-x(Ｖ)xO （2）
Ｍ1-x(Ｖ)x(CO3) （3）
ただし ＭはＭｇまたはＣａの少なくとも1種をあらわし、ｘの値は、0＜ｘ≦0.1、好ましくは0＜ｘ≦0.05である。ｘ値が0.1を超えると人体に悪影響を及ぼす可能性が出てくる。
The present inventor is represented by the following formulas (1), (2), and (3) in which a minute amount of vanadium ion, which is one of minerals required by humans, is dissolved in Mg or / and a Ca compound. It has been found that blood sugar levels can be lowered by oral administration of inorganic compounds.
M 1-x (V) x (OH) 2 (1)
M 1-x (V) x O (2)
M 1-x (V) x (CO 3 ) (3)
However, M represents at least one of Mg or Ca, and the value of x is 0 <x ≦ 0.1, preferably 0 <x ≦ 0.05. If the x value exceeds 0.1, the human body may be adversely affected.
本発明の無機化合物粒子は、膵臓機能の強化乃至活性化に優れた効果があるのみならず、バナジウム（Ｖ）及びマグネシウム（Ｍｇ）またはカルシウム（Ｃａ）補給に効果的である。 The inorganic compound particles of the present invention are effective not only in enhancing or activating pancreatic function but also in supplementing vanadium (V) and magnesium (Mg) or calcium (Ca).
本発明の式（１）、（2）および（3）で表される無機化合物粒子は、本発明者が見出した新規な化合物で、Ｍｇまたは／及びＣａの水酸化物、酸化物、炭酸化物に微量のバナジウムが固溶したものである。これは、ＭｇまたはＣａの水酸化物、酸化物、炭酸化物粒子と同じ結晶構造を有する化合物であり、粉末X線回折法によれば、ＭｇまたはＣａの水酸化物、酸化物、炭酸化物粒子と同じ回折パターンを示す。 The inorganic compound particles represented by the formulas (1), (2) and (3) of the present invention are novel compounds found by the present inventors, and are hydroxides, oxides and carbonates of Mg or / and Ca. In which a small amount of vanadium is dissolved. This is a compound having the same crystal structure as the hydroxide, oxide or carbonate particles of Mg or Ca. According to the powder X-ray diffraction method, the hydroxide, oxide or carbonate particles of Mg or Ca Shows the same diffraction pattern.
本発明の無機化合物の製造方法は、マグネシウムイオン、または／及びカルシウムイオンとバナジウムイオンを含有する水溶液に、これらカチオンの合計当量に対してほぼ当量以下のアルカリ性物質または炭酸ソーダを加え、攪拌下に反応させ、必要に応じさらに反応物を常温〜200℃でオートクレーブを用いて、水熱処理してもよい。その後、水洗、脱水、乾燥する。ついで約300〜1200℃、好ましくは、400〜900℃で約0.1〜10時間焼成した後、粉砕、分級等の慣用の手段を適宜選択して採用することにより、製造される。 In the method for producing an inorganic compound of the present invention, an alkaline substance or sodium carbonate having an equivalent amount of less than or equal to the total equivalent of these cations is added to an aqueous solution containing magnesium ions or / and calcium ions and vanadium ions. If necessary, the reaction product may be further hydrothermally treated at room temperature to 200 ° C. using an autoclave. Then, it is washed with water, dehydrated and dried. Then, after baking at about 300 to 1200 ° C., preferably at 400 to 900 ° C. for about 0.1 to 10 hours, conventional means such as pulverization and classification are appropriately selected and employed.
本発明の無機化合物粒子を、血糖値降下剤として、または膵臓の機能強化乃至活性化剤として、膵臓病の予防ないし治療薬として使用する場合は、粉末状、顆粒状、錠剤、カプセル剤または、スラリー状のいずれの形態でもよく、ビタミンや他のミネラル、アミノ酸、ピコリン酸、酢酸、クエン酸、グリセリン酸、モノメチオニン、賦形剤、結合剤、崩壊剤および滑沢剤等を必要に応じ添加することが出来る。 When the inorganic compound particles of the present invention are used as a hypoglycemic agent, as a pancreatic function enhancement or activator, or as a prophylactic or therapeutic agent for pancreatic disease, powder, granule, tablet, capsule, or Any form of slurry may be used, vitamins and other minerals, amino acids, picolinic acid, acetic acid, citric acid, glyceric acid, monomethionine, excipients, binders, disintegrants and lubricants added as necessary I can do it.
本発明の無機化合物を錠剤とする場合、無機化合物粒子はレーザー回折散乱法で測定された平均2次粒子径が1〜30μｍ、好ましくは５〜20μmであり、そのため打錠機を磨耗せず、またBET法にて測定した比表面積が、1〜60m2／g、好ましくは5〜40m2／gである無機化合物粒子が錠剤化もしやすい。 When the inorganic compound of the present invention is used as a tablet, the inorganic compound particles have an average secondary particle diameter of 1 to 30 μm, preferably 5 to 20 μm, measured by a laser diffraction scattering method, and therefore do not wear the tableting machine. In addition, inorganic compound particles having a specific surface area measured by the BET method of 1 to 60 m 2 / g, preferably 5 to 40 m 2 / g, are easily tableted.
この平均粒子径を有する無機化合物粒子を使用し、後述の結合剤と崩壊剤とを組み合わせることによって錠剤中の無機化合物粒子が85重量％〜97重量％、好ましくは88重量％〜96重量％、特に好ましくは、90重量％〜95重量％と高含有量化することが出来る。錠剤化に供する無機化合物粒子は粉末状でも顆粒状でもよい。 Using inorganic compound particles having this average particle diameter, the inorganic compound particles in the tablet are 85% by weight to 97% by weight, preferably 88% by weight to 96% by weight, by combining the below-described binder and disintegrant. Particularly preferably, the content can be increased to 90 to 95% by weight. The inorganic compound particles used for tableting may be powdered or granular.
本発明の無機化合物粒子錠剤に使用される結合剤としては、カルボキシメチルセルロースナトリウム、低置換度ヒドロキシプロピルセルロース、結晶セルロース、またはデンプン（例えばトウモロコシデンプン）であり、錠剤中1〜10重量％、好ましくは１〜８重量％配合され、また崩壊剤としては、カルボキシメチルセルロースカルシウム、カルメロース、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム、カルメロースカルシウムまたは、カルボキシスターチナトリウム、不溶性ポリビニルピロリドンである。これら崩壊剤は２種以上組み合わせても良い。崩壊剤としては、特に、クロスカルメロースナトリウム、カルボキシスターチナトリウム、不溶性ポリビニルピロリドン等は、従来の崩壊剤に比べて、極めて少量で崩壊するので、その配合量を減らすことが出来、さらに、経時的変化が非常に少なく、錠剤に配合した場合は、安定性に優れた錠剤を得ることが出来る。最も好ましい崩壊剤はクロスカルメロ-スナトリウムである。崩壊剤は錠剤中１〜10重量％、好ましくは１〜5重量％配合される。 The binder used in the inorganic compound particle tablet of the present invention is sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, crystalline cellulose, or starch (eg corn starch), preferably 1 to 10% by weight in the tablet, preferably 1 to 8% by weight, and the disintegrant is carboxymethylcellulose calcium, carmellose, low-substituted hydroxypropylcellulose, croscarmellose sodium, carmellose calcium or carboxystarch sodium, insoluble polyvinylpyrrolidone. Two or more of these disintegrants may be combined. As disintegrants, especially croscarmellose sodium, carboxystarch sodium, insoluble polyvinylpyrrolidone and the like disintegrate in an extremely small amount compared to conventional disintegrants, so the blending amount can be reduced, and moreover, The change is very small, and when blended in a tablet, a tablet having excellent stability can be obtained. The most preferred disintegrant is croscarmellose sodium. The disintegrant is contained in the tablet in an amount of 1 to 10% by weight, preferably 1 to 5% by weight.
顆粒の造粒は、結合剤および崩壊剤を配合した無機化合物粒子を乾式造粒し、顆粒とするのであるが、この場合の混合は(1)無機化合物粒子85〜97重量％(2)結合剤1〜10重量％（好ましくは1〜8重量％）(3)崩壊剤1〜10重量％（好ましくは1〜5重量％）の組成で、コンテナー型、V型あるいはW型などの混合器を用いて混合し、顆粒状粒子に造粒する。その造粒は低圧力で乾式造粒機を用いて行うのが好ましく、この場合のロール圧は3〜12MPaが好ましく、さらに好ましくは、4〜8MPaである。造粒したシート状成形物は、オシレーター式粉砕機にて顆粒状粒子を得る。オシレーターに装着するスクリーンは目開き0.7〜1.2ｍｍが好ましく、0.8〜1.0mmがより好ましい。かくして、平均粒子径が、0.25〜2.00mm、かつ見掛け密度が0.5〜0.7ｇ／mLの顆粒状粒子が得られる。 Granules are granulated by dry granulation of inorganic compound particles containing a binder and a disintegrant to form granules. In this case, mixing is (1) 85 to 97% by weight of inorganic compound particles (2) binding 1 to 10% by weight (preferably 1 to 8% by weight) of agent (3) 1 to 10% by weight (preferably 1 to 5% by weight) of disintegrant, container type, V type or W type mixer And granulate into granular particles. The granulation is preferably carried out at a low pressure using a dry granulator. In this case, the roll pressure is preferably 3 to 12 MPa, more preferably 4 to 8 MPa. The granulated sheet-like molded product obtains granular particles with an oscillator-type pulverizer. The screen attached to the oscillator preferably has an aperture of 0.7 to 1.2 mm, more preferably 0.8 to 1.0 mm. Thus, granular particles having an average particle diameter of 0.25 to 2.00 mm and an apparent density of 0.5 to 0.7 g / mL are obtained.
錠剤に製剤する場合は、結合剤、崩壊剤、賦形剤および滑沢剤等を配合し、直接打錠法により製造してもよいが、上記の顆粒に、0.2〜２重量％の滑沢剤を加え、製錠してもよい。この場合の顆粒の平均粒子径は0.25〜0.40ｍｍが好ましい。結合剤は、前述の結合剤の1種以上を錠剤中1〜10重量％、好ましくは1〜5重量％含有されるよう配合する。また崩壊剤は、前述の崩壊剤の1種以上を錠剤中5〜20重量％、好ましくは5〜10重量％含有される。硬い粒子の無機化合物粒子を用いた場合は、錠剤の崩壊時間が遅く、血糖降下の効果が遅くなるので、無機化合物粒子と崩壊剤を特定して、崩壊が早い錠剤を得ることが望ましく、更に顆粒成形時の乾式造粒の圧力は、4〜8MPaが好ましい。 When it is formulated into a tablet, it may be produced by blending a binder, a disintegrant, an excipient, a lubricant, and the like and directly manufactured by tableting. However, 0.2 to 2% by weight of lubricant is added to the granule. An agent may be added to make a tablet. In this case, the average particle size of the granules is preferably 0.25 to 0.40 mm. The binder is blended so as to contain 1 to 10% by weight, preferably 1 to 5% by weight, of the above-mentioned binder in the tablet. Further, the disintegrant contains 5 to 20% by weight, preferably 5 to 10% by weight, in the tablet of one or more of the aforementioned disintegrants. When the inorganic compound particles of hard particles are used, the disintegration time of the tablet is slow and the effect of lowering blood sugar is slow. Therefore, it is desirable to specify the inorganic compound particles and the disintegrant to obtain a tablet that disintegrates quickly. The pressure for dry granulation at the time of granulation is preferably 4 to 8 MPa.
実施例に基づき、本発明を詳細に説明する。
実施例において、無機粒子の（a）Ｖの分析値、（ｂ）平均2次粒子径、（ｃ）BET法比表面積は以下に記載する測定法によって測定された値を意味する。
（a）Ｖの分析
原子吸光法により測定した。
（ｂ）平均2次粒子径
MICROTRAC粒度分布計SPAタイプ（LEEDS＆NORTHRUP INSTRUMENTS社製）を用いて測定決定する。
試料粉末700ｍｇを70ｍLの水に加えて、超音波（NISSEI社製、MODEL US-300,電流300μA）で3分間分散処理した後、その分散液の2-4ｍLを採って、250ｍLの脱気水を収容した上記粒度分布計の試料室に加え、分析計を作動させて8分間その懸濁液を循環した後、粒度分布を測定する。合計2回の測定を行い、それぞれの測定について得られた50％累積2次粒子径の算術平均値を算出して、試料の平均2次粒子径とする。
（ｃ）BET法比表面積
液体窒素の吸着法により測定した。
The present invention will be described in detail based on examples.
In Examples, (a) V analysis value, (b) average secondary particle size, and (c) BET specific surface area of inorganic particles mean values measured by the measurement methods described below.
(A) Analytical measurement of V Measured by atomic absorption.
(B) Average secondary particle size
Measurement is determined using a MICROTRAC particle size distribution analyzer SPA type (manufactured by LEEDS & NORTHHRUP INSTRUMENTS).
Add 700 mg of the sample powder to 70 mL of water, disperse with ultrasonic waves (NISSEI, MODEL US-300, current 300 μA) for 3 minutes, take 2-4 mL of the dispersion, and then add 250 mL of deaerated water. In addition to the sample chamber of the particle size distribution meter containing the above, the analyzer is operated and the suspension is circulated for 8 minutes, and then the particle size distribution is measured. The measurement is performed twice in total, and the arithmetic average value of the 50% cumulative secondary particle diameter obtained for each measurement is calculated to obtain the average secondary particle diameter of the sample.
(C) BET method Specific surface area It was measured by the liquid nitrogen adsorption method.
硝酸マグネシウムと塩化バナジウム混合水溶液(硝酸マグネシウム1.30モル／L、塩化バナジウム1.3×10-4モル／L、Ａ液とする)と6.5Ｎの水酸化ナトリウム液（Ｂ液とする）とを定量ポンプを用いて、あらかじめ水を入れ攪拌している反応槽にＡ液及びＢ液を連続して注加する。
反応温度40℃、反応pH10.5、反応槽での反応液の滞留時間は30分間で行い、反応槽からオーバーフローした反応懸濁液を4時間取り出した。
反応液を濾別、水洗し、110℃で24時間乾燥後、粉砕、篩過して、次に示す組成のマグネシウム化合物粒子の水酸化物を得た。
組成：Mg0.9999Ｖ0.0001 (OH)2
次に、上記マグネシウム化合物粒子水酸化物を焼成炉にて、700℃で2時間焼成し、次に示す組成のマグネシウム化合物粒子を得た。
組成：Mg0.9999Ｖ0.0001O
A metering pump for magnesium nitrate and vanadium chloride mixed aqueous solution (magnesium nitrate 1.30 mol / L, vanadium chloride 1.3 × 10 -4 mol / L, liquid A) and 6.5 N sodium hydroxide liquid (liquid B) The liquid A and the liquid B are continuously poured into a reaction vessel in which water is previously added and stirred.
The reaction temperature was 40 ° C., the reaction pH was 10.5, and the residence time of the reaction liquid in the reaction tank was 30 minutes, and the reaction suspension overflowed from the reaction tank was taken out for 4 hours.
The reaction solution was filtered off, washed with water, dried at 110 ° C. for 24 hours, pulverized and sieved to obtain magnesium compound particle hydroxide having the following composition.
Composition: Mg 0.9999 V 0.0001 (OH) 2
Next, the magnesium compound particle hydroxide was fired in a firing furnace at 700 ° C. for 2 hours to obtain magnesium compound particles having the following composition.
Composition: Mg 0.9999 V 0.0001 O
試薬硝酸マグネシウムと塩化バナジウムとの混合水溶液（硝酸マグネシウム1.30モル／L,塩化バナジウム1.31×10-2モル／L、A液とする）と6.5Nの水酸化ナトリウム水溶液（B液とする）とを実施例1と同様の方法で反応を行い、反応槽からオーバーフローした反応懸濁液700ｍLをオートクレーブ装置に移して100℃で3時間水熱反応させた。冷却後濾別、水洗し110℃で24時間乾燥後、粉砕、篩過して下記組成の水酸化マグネシウム化合物粒子を得た。
組成：Mg0.990Ｖ0.010(OH)2
次に上記水酸化マグネシウム化合物粒子を焼成炉で700℃で2時間焼成し、次に示す組成の酸化マグネシウム化合物粒子を得た。
組成：Mg0.990Ｖ0.010O
A mixed aqueous solution of reagent magnesium nitrate and vanadium chloride (magnesium nitrate 1.30 mol / L, vanadium chloride 1.31 × 10 -2 mol / L, liquid A) and 6.5N sodium hydroxide aqueous solution (liquid B) Reaction was carried out in the same manner as in Example 1, and 700 mL of the reaction suspension overflowed from the reaction tank was transferred to an autoclave apparatus and subjected to hydrothermal reaction at 100 ° C. for 3 hours. After cooling, it was filtered, washed with water, dried at 110 ° C. for 24 hours, pulverized and sieved to obtain magnesium hydroxide compound particles having the following composition.
Composition: Mg 0.990 V 0.010 (OH) 2
Next, the magnesium hydroxide compound particles were fired in a firing furnace at 700 ° C. for 2 hours to obtain magnesium oxide compound particles having the following composition.
Composition: Mg 0.990 V 0.010 O
試薬硝酸マグネシウムと塩化バナジウム水溶液（硝酸マグネシウム1.30モル／L,塩化バナジウム0.144モル／L、A液とする）と6.5Nの水酸化ナトリウム水溶液（B液とする）とを実施例1と同様の方法で反応を行い、反応槽からオーバーフローした反応懸濁液700ｍLをオートクレーブ装置に移して100℃で3時間水熱反応させた。冷却後濾別、水洗し110℃で24時間乾燥後、粉砕、篩過して下記組成の水酸化マグネシウム化合物粒子を得た。
組成：Mg0.90Ｖ0.10(OH)2
次に水酸化マグネシウム化合物粒子を焼成炉で700℃で2時間焼成し、次に示す組成の複合酸化マグネシウム粒子を得た。
組成：Mg0.90Ｖ0.10O
The same method as in Example 1 with the reagent magnesium nitrate and vanadium chloride aqueous solution (magnesium nitrate 1.30 mol / L, vanadium chloride 0.144 mol / L, liquid A) and 6.5 N sodium hydroxide aqueous solution (liquid B) Then, 700 mL of the reaction suspension overflowed from the reaction vessel was transferred to an autoclave apparatus and subjected to hydrothermal reaction at 100 ° C. for 3 hours. After cooling, it was filtered, washed with water, dried at 110 ° C. for 24 hours, pulverized and sieved to obtain magnesium hydroxide compound particles having the following composition.
Composition: Mg 0.90 V 0.10 (OH) 2
Next, the magnesium hydroxide compound particles were calcined at 700 ° C. for 2 hours in a calcining furnace to obtain composite magnesium oxide particles having the following composition.
Composition: Mg 0.90 V 0.10 O
実施例1および2で得られた酸化物サンプルを用い、ラットによる耐糖能試験を行った。
（試験方法）
一晩（２０時間以上）絶食させたラット（ＳＤ系 雄 6〜7週齢、6匹/サンプル）を使用した。
グルコースを1ｇ/10ｍＬ/Ｋｇでラットに経口投与した後、直ちに資料であるハイドロタルサイト類化合物粒子10ｍＬ/Ｋｇを、ディスポーザブル注射筒及びらと用胃ゾンデを用いて強制的に経口投与した。試料投与前、投与３０分及び６０分後に、それぞれ尾静脈より採血し、小型電極式血糖測定機器（アントセンスII, ダイキン工業（株））を用いて血糖値を測定した。
結果を表1に示す。
Using the oxide samples obtained in Examples 1 and 2, a glucose tolerance test using rats was performed.
(Test method)
Rats (SD male 6-7 weeks old, 6 animals / sample) fasted overnight (over 20 hours) were used.
Glucose was orally administered to rats at 1 g / 10 mL / Kg, and immediately after that, 10 mL / Kg of hydrotalcite compound particles as a document was forcibly orally administered using a disposable syringe and a gastric sonde. Before sample administration, 30 minutes and 60 minutes after administration, blood was collected from the tail vein, and the blood glucose level was measured using a small electrode blood glucose measurement device (Antosense II, Daikin Industries, Ltd.).
The results are shown in Table 1.
Claims (11)
Ｍ1-x(Ｖ)x(OH)2 （1）
Ｍ1-x(Ｖ)xO （2）
Ｍ1-x(Ｖ)x(CO3) （3）
（ただし ＭはＭｇまたはＣａの少なくとも1種をあらわし、ｘは下記範囲を示す。
0＜ｘ≦0.1） Inorganic compound particles for enhancing or activating pancreatic function represented by the following formula (1) or (2).
M 1-x (V) x (OH) 2 (1)
M 1-x (V) x O (2)
M 1-x (V) x (CO 3 ) (3)
(However, M represents at least one of Mg or Ca, and x represents the following range.
0 <x ≦ 0.1)
A tablet for enhancing or activating pancreatic function, comprising the inorganic compound particles according to claim 1 in a proportion of 85 to 97% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009237888A JP5390334B2 (en) | 2009-10-15 | 2009-10-15 | A blood glucose level lowering agent or pancreatic function enhancing or activating agent comprising vanadium solid solution magnesium oxide compound particles as an active ingredient. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009237888A JP5390334B2 (en) | 2009-10-15 | 2009-10-15 | A blood glucose level lowering agent or pancreatic function enhancing or activating agent comprising vanadium solid solution magnesium oxide compound particles as an active ingredient. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011084505A true JP2011084505A (en) | 2011-04-28 |
| JP2011084505A5 JP2011084505A5 (en) | 2011-08-11 |
| JP5390334B2 JP5390334B2 (en) | 2014-01-15 |
Family
ID=44077737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009237888A Expired - Fee Related JP5390334B2 (en) | 2009-10-15 | 2009-10-15 | A blood glucose level lowering agent or pancreatic function enhancing or activating agent comprising vanadium solid solution magnesium oxide compound particles as an active ingredient. |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5390334B2 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539306A (en) * | 1966-07-25 | 1970-11-10 | Kyowa Chem Ind Co Ltd | Process for the preparation of hydrotalcite |
| JP2000044584A (en) * | 1998-07-31 | 2000-02-15 | Japan Science & Technology Corp | 'amino acid derivative'-oxovanadium(iv) complex |
| JP2000281650A (en) * | 1999-03-30 | 2000-10-10 | Japan Science & Technology Corp | 2-mercapto-pyridine-n-oxide derivative and oxovanadium (iv) complex |
| JP2001011083A (en) * | 1999-06-29 | 2001-01-16 | Japan Science & Technology Corp | Bis(halopicolinate)oxovanadium |
| WO2007043606A1 (en) * | 2005-10-12 | 2007-04-19 | Genolac Bl Corporation | Antidiabetic agent comprising anionic polyamino acid-metal complex |
| JP2011088870A (en) * | 2009-10-26 | 2011-05-06 | Kyowa Chem Ind Co Ltd | Aluminum compound particle for enhancing or activating pancreas function |
-
2009
- 2009-10-15 JP JP2009237888A patent/JP5390334B2/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539306A (en) * | 1966-07-25 | 1970-11-10 | Kyowa Chem Ind Co Ltd | Process for the preparation of hydrotalcite |
| JP2000044584A (en) * | 1998-07-31 | 2000-02-15 | Japan Science & Technology Corp | 'amino acid derivative'-oxovanadium(iv) complex |
| JP2000281650A (en) * | 1999-03-30 | 2000-10-10 | Japan Science & Technology Corp | 2-mercapto-pyridine-n-oxide derivative and oxovanadium (iv) complex |
| JP2001011083A (en) * | 1999-06-29 | 2001-01-16 | Japan Science & Technology Corp | Bis(halopicolinate)oxovanadium |
| WO2007043606A1 (en) * | 2005-10-12 | 2007-04-19 | Genolac Bl Corporation | Antidiabetic agent comprising anionic polyamino acid-metal complex |
| JP2011088870A (en) * | 2009-10-26 | 2011-05-06 | Kyowa Chem Ind Co Ltd | Aluminum compound particle for enhancing or activating pancreas function |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5390334B2 (en) | 2014-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6938425B2 (en) | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and its production and usage | |
| CN101754751B (en) | Mixed metal compounds used as antacids | |
| CN107929313B (en) | Natural oyster calcium carbonate preparation for preventing and treating calcium deficiency and preparation method thereof | |
| TWI477294B (en) | Use for magnesium oxide particle | |
| JP6343338B2 (en) | Magnesium oxide granules for pharmaceutical or food use | |
| CA2748496C (en) | Disintegrable formulations of lanthanum carbonate | |
| CN107281218A (en) | A kind of high-selenium corn is combined calcium-supplementing preparation and preparation method thereof | |
| JP5352416B2 (en) | A blood glucose level lowering agent comprising vanadium-containing aluminum compound as an active ingredient | |
| JP5352411B2 (en) | Hypoglycemic agent or pancreatic function enhancing or activating agent comprising hydrotalcite compound particles as an active ingredient | |
| JP5390334B2 (en) | A blood glucose level lowering agent or pancreatic function enhancing or activating agent comprising vanadium solid solution magnesium oxide compound particles as an active ingredient. | |
| JPWO2010098417A1 (en) | Magnesium oxide fine granules | |
| JP2011088870A5 (en) | ||
| JP2011084491A5 (en) | ||
| JP2011084505A5 (en) | ||
| JP2010265208A (en) | Composite magnesium oxide particle for enhancing or activating pancreatic function | |
| CN102151286B (en) | Hydrotalcite tablet and preparation method thereof | |
| TWI448299B (en) | A binder for forming a tablet | |
| JP7240700B2 (en) | How to evenly disperse minerals in granulated powder | |
| JP5160156B2 (en) | Nutritional functional food tablets | |
| JP2010265207A (en) | Composite hydrotalcite particle for enhancing or activating pancreatic function | |
| JP2006345720A (en) | Calcium preparation and method for producing the same | |
| WO2018030225A1 (en) | Magnesium oxide granules | |
| KR100788454B1 (en) | Rapid-acting fomulation containing nateglinide as an active ingredient | |
| CN111789819B (en) | Tablet containing Cetilistat and preparation method thereof | |
| JP2009263301A (en) | Ulcer treating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110621 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110621 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130617 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130906 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131001 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131010 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5390334 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |